Diabetes is a common disease, with figures showing that about 6% of the global population is afflicted by the ailment. Since 1990, rates of the disease have been increasing, with estimates showing that this trend is expected to continue for at least two more decades. Now new research has found that type 2 diabetes is more common in individuals with psychiatric disorder, in comparison with other people.
The research was carried out by a team of researchers from the University of Southern Denmark, led by Nanna Lindekilde of the school’s psychology department. Its findings were reported in “Diabetologia.”
Psychiatric disorders are known to diminish an individual’s quality of life and are linked to heighted rates of mortality. It is believed that the increased mortality rates are partly caused by more accidents and suicides as well as by a higher risk of developing physical conditions associated with mental health issues, which include respiratory and cardiovascular ailments.
Prior research discovered that the prevalence of this type of diabetes was higher in individuals with major depressive disorder, bipolar disorder and schizophrenia, in comparison to the general populace.
For their study, the researchers carried out an extensive search of various e-databases of scientific papers, finding more than 30 systematic reviews based on 245 primary studies. The categories of the disorders assessed in the studies include eating disorder, anxiety disorder, substance-use disorder, depression, bipolar disorder, schizophrenia, dementia, sleep disorder, psychosis, intellectual disability and a group made up of different psychiatric disorders.
The researchers found that individuals suffering from sleep disorders had the highest type 2 diabetes rates, at 40%. The disease’s prevalence in other psychiatric disorders was 11% for patients with psychosis and bipolar disorder, 14% for those with anxiety disorders, 16% for individuals with substance use disorder, and 21% for those afflicted with binge-eating disorder.
In their report, the researchers highlighted that while individuals suffering from any of the disorders studied had higher chances of having type 2 diabetes in comparison to the general populace, more elaborate comparisons needed to be made between prevalence estimates to account for differences in study settings and population groups.
The researchers note in their conclusion that type 2 diabetes’ prevalence among people with psychiatric disorders suggests that the ailments have a shared vulnerability, adding that understanding the behavioral and biological factors driving increased prevalence of the disease in those with psychiatric disorders better will be critical in the development of effective strategies for patient management.
The study clearly shows how vital it is to address psychiatric disorders as soon as possible before additional complications set in, and that is why the work of companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), which are developing new medicines targeting mental disorders, deserve any support available.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.